Alpha Tau Medical Ltd.
DRTSHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Alpha Tau Medical Ltd. (DRTS) is listed under Biotechnology. At a $1.37B market cap, Alpha Tau Medical Ltd. ranks as a small-cap company within healthcare. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors.
Market Cap
$1.37B
Beta
1.21
P/E (TTM)
—
P/E (Fwd)
-28.40
EPS (TTM)
$-1.04
EPS (Fwd)
$-0.52
ROE
-141.7%
ROA
-25.7%
Cash
$100.6M
Total Debt
$15.2M
Free CF
-$20.3M
52W Change
300.8%
Annual Financials
Cash vs Debt
Where DRTS stands vs its 150-day and 200-day moving averages
As of the September 2, 2026 close, DRTS finished 42.74% above its 150-day moving average ($9.78) and 61.95% above its 200-day moving average ($8.62). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is DRTS overbought or oversold?
At the September 2, 2026 close, DRTS's RSI(14) was 51.3, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $100.6M in cash comfortably exceeding the $15.2M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$20.3M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -141.7%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing DRTS.